Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on angiogenesis inhibitors.

Anaadriana Zakarija1, Gerald Soff

  • 1Divison of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.

Current Opinion in Oncology
|October 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism in women who undergo neoadjuvant chemotherapy for advanced ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2023
Same author

Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy.

Journal of thrombosis and haemostasis : JTH·2023
Same author

A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura.

British journal of haematology·2023
Same author

Application of Machine Learning to the Prediction of Cancer-Associated Venous Thromboembolism.

Research square·2023
Same author

Hereditary thrombotic thrombocytopenic purpura acquired through liver transplantation: A case report.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2023
Same author

Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2022
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

New anti-angiogenesis therapies show promise in clinical trials. Bevacizumab (Avastin) is approved for metastatic colorectal cancer, demonstrating survival benefits with chemotherapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
  • Several therapeutic agents targeting angiogenesis have been developed.

Purpose of the Study:

  • To review recent clinical trial data on promising angiogenesis inhibitors.
  • To highlight advancements in anti-angiogenic therapies.

Main Methods:

  • Review of recent clinical trial data.
  • Focus on agents targeting the vascular endothelial growth factor (VEGF) signaling pathway.

Main Results:

  • Bevacizumab (Avastin), an anti-VEGF monoclonal antibody, received FDA approval.
  • Bevacizumab demonstrated a survival advantage in metastatic colorectal cancer when combined with chemotherapy.

Related Experiment Videos

  • Other promising agents include PTK787/ZK 222584 (Vatalanib), ZD6474, and BAY 43-9006 (Sorafenib).

    • Conclusions:

    • Angiogenesis inhibitors hold significant therapeutic promise.
    • Evaluating optimal efficacy is challenging due to differing mechanisms of action and lack of surrogate markers.